Marktanalyse - Sicca Syndrome (Sjogren) - Pipeline Review, H2 2016

Global Markets Direct
12.2016
97 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Sicca Syndrome (Sjogren) - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sicca Syndrome (Sjogren) — Pipeline Review, H2 2016, provides an overview of the Sicca Syndrome (Sjogren) (Immunology) pipeline landscape.

Sjogren's syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling and stiffness. Predisposing factors include age, sex and rheumatic disease.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sicca Syndrome (Sjogren) — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sicca Syndrome (Sjogren) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 10, 6 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Sicca Syndrome (Sjogren) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Sicca Syndrome (Sjogren) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sicca Syndrome (Sjogren) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sicca Syndrome (Sjogren) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sicca Syndrome (Sjogren) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sicca Syndrome (Sjogren) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Sicca Syndrome (Sjogren) Overview 8

Therapeutics Development 9

Pipeline Products for Sicca Syndrome (Sjogren) - Overview 9

Pipeline Products for Sicca Syndrome (Sjogren) - Comparative Analysis 10

Sicca Syndrome (Sjogren) - Therapeutics under Development by Companies 11

Sicca Syndrome (Sjogren) - Therapeutics under Investigation by Universities/Institutes 13

Sicca Syndrome (Sjogren) - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Sicca Syndrome (Sjogren) - Products under Development by Companies 17

Sicca Syndrome (Sjogren) - Products under Investigation by Universities/Institutes 18

Sicca Syndrome (Sjogren) - Companies Involved in Therapeutics Development 19

Akari Therapeutics Plc 19

Amgen Inc 20

Ampio Pharmaceuticals Inc 21

Atlantic Bio Sci LLC 22

Biogen Inc 23

Bristol-Myers Squibb Company 24

Eli Lilly and Company 25

F. Hoffmann-La Roche Ltd 26

GlaxoSmithKline Plc 27

MedImmune LLC 28

Novartis AG 29

Redx Pharma Plc 30

Resolve Therapeutics LLC 31

Samjin Pharmaceutical Co Ltd 32

UCB SA 33

Sicca Syndrome (Sjogren) - Therapeutics Assessment 34

Assessment by Monotherapy Products 34

Assessment by Combination Products 35

Assessment by Target 36

Assessment by Mechanism of Action 38

Assessment by Route of Administration 40

Assessment by Molecule Type 42

Drug Profiles 44

abatacept - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

ABS-11 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

AMG-557 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Ampion - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

belimumab - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

belimumab + rituximab - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

BIIB-063 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

BMS-986142 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

CDZ-173 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Cellular Immunotherapy for Type 1 Diabetes and Sjogrens Syndrome - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

CFZ-533 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Coversin - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

GSK-2618960 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

IMSO-001 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

lulizumab pegol - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

LY-3090106 - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

MEDI-4920 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

MEDI-7734 - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

RDX-002 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

RG-7625 - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

RSLV-132 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

SA-001 - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

seletalisib - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

VAY-736 - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

VM-200 - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

Sicca Syndrome (Sjogren) - Dormant Projects 93

Sicca Syndrome (Sjogren) - Discontinued Products 94

Sicca Syndrome (Sjogren) - Product Development Milestones 95

Featured News & Press Releases 95

Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogren’s syndrome 95

Appendix 96

Methodology 96

Coverage 96

Secondary Research 96

Primary Research 96

Expert Panel Validation 96

Contact Us 96

Disclaimer 97





List of Tables

Number of Products under Development for Sicca Syndrome (Sjogren), H2 2016 9

Number of Products under Development for Sicca Syndrome (Sjogren) - Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Development, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Investigation by Universities/Institutes, H2 2016 18

Sicca Syndrome (Sjogren) - Pipeline by Akari Therapeutics Plc, H2 2016 19

Sicca Syndrome (Sjogren) - Pipeline by Amgen Inc, H2 2016 20

Sicca Syndrome (Sjogren) - Pipeline by Ampio Pharmaceuticals Inc, H2 2016 21

Sicca Syndrome (Sjogren) - Pipeline by Atlantic Bio Sci LLC, H2 2016 22

Sicca Syndrome (Sjogren) - Pipeline by Biogen Inc, H2 2016 23

Sicca Syndrome (Sjogren) - Pipeline by Bristol-Myers Squibb Company, H2 2016 24

Sicca Syndrome (Sjogren) - Pipeline by Eli Lilly and Company, H2 2016 25

Sicca Syndrome (Sjogren) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 26

Sicca Syndrome (Sjogren) - Pipeline by GlaxoSmithKline Plc, H2 2016 27

Sicca Syndrome (Sjogren) - Pipeline by MedImmune LLC, H2 2016 28

Sicca Syndrome (Sjogren) - Pipeline by Novartis AG, H2 2016 29

Sicca Syndrome (Sjogren) - Pipeline by Redx Pharma Plc, H2 2016 30

Sicca Syndrome (Sjogren) - Pipeline by Resolve Therapeutics LLC, H2 2016 31

Sicca Syndrome (Sjogren) - Pipeline by Samjin Pharmaceutical Co Ltd, H2 2016 32

Sicca Syndrome (Sjogren) - Pipeline by UCB SA, H2 2016 33

Assessment by Monotherapy Products, H2 2016 34

Assessment by Combination Products, H2 2016 35

Number of Products by Stage and Target, H2 2016 37

Number of Products by Stage and Mechanism of Action, H2 2016 39

Number of Products by Stage and Route of Administration, H2 2016 41

Number of Products by Stage and Molecule Type, H2 2016 43

Sicca Syndrome (Sjogren) - Dormant Projects, H2 2016 93

Sicca Syndrome (Sjogren) - Discontinued Products, H2 2016 94





List of Figures

Number of Products under Development for Sicca Syndrome (Sjogren), H2 2016 9

Number of Products under Development for Sicca Syndrome (Sjogren) - Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy Products, H2 2016 34

Number of Products by Top 10 Targets, H2 2016 36

Number of Products by Stage and Top 10 Targets, H2 2016 36

Number of Products by Top 10 Mechanism of Actions, H2 2016 38

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 38

Number of Products by Routes of Administration, H2 2016 40

Number of Products by Stage and Routes of Administration, H2 2016 40

Number of Products by Molecule Types, H2 2016 42

Number of Products by Stage and Molecule Types, H2 2016 42

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus